Eyes, the brain and the burden of pain shape how we experience the world, and when disease strikes, lives can be profoundly affected. Building on over 130 years of independence, Dompé is harnessing the full potential of nerve growth factor (NGF) to develop first-in-class disease-modifying therapies across ophthalmic, neurological and pain-related indications to help improve patients’ lives.
Watch our new corporate video and discover our commitment to bringing the full potential of NGF to patients.
Dompé U.S. Inc. is part of the Dompé farmaceutici S.p.A., parent company of the Dompé operating companies, with headquarters in Milan, Italy. We are an international biopharmaceutical company active across the entire pharmaceutical value chain, from research to development, production and commercialization.
